Cancer Research Donn Young Protein Translation and Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
[Cancer Research 54, 2771-2777, May 15, 1994]
© 1994 American Association for Cancer Research
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Press, M. F.
Right arrow Articles by Slamon, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Press, M. F.
Right arrow Articles by Slamon, D. J.

Sensitivity of HER-2/neu Antibodies in Archival Tissue Samples: Potential Source of Error in Immunohistochemical Studies of Oncogene Expression1

Michael F. Press2, Gene Hung, William Godolphin and Dennis J. Slamon

Department of Pathology, University of Southern California School of Medicine, Los Angeles, California 90033 [M. F. P., G. H.]; Division of Clinical Chemistry, Vancouver General Hospital, Vancouver, British Columbia, Canada [W. G.]; and Division of Hematology-Oncology, U.C.L.A. School of Medicine, Los Angeles, California 90024 [D. J. S.]

HER-2/neu oncogene amplification and overexpression of breast cancer tissue has been correlated with poor prognosis in women with both node-positive and node-negative disease. However, several studies have not confirmed this association. Review of these studies reveals the presence of considerable methodological variability including differences in study size, follow-up time, techniques and reagents. The majority of papers with clinical follow-up information are immunohistochemical studies using archival, paraffin-embedded breast cancers, and a variety of HER-2/neu antibodies have been used in these studies. Very little information, however, is available about the ability of the antibodies to detect overexpression following tissue processing for paraffin-embedding. Therefore, a series of antibodies, reported in the literature or commercially available, were evaluated to assess their sensitivity and specificity as immunohistochemical reagents. Paraffin-embedded samples of 187 breast cancers, previously characterized as frozen specimens for HER-2/neu amplification by Southern blot and for overexpression by Northern blot, Western blot, and immunohistochemistry, were used. Two multitumor paraffin-embedded tissue blocks were prepared from the previously analyzed breast cancers as a panel of cases to test a series of previously studied and/or commercially available anti-HER-2/neu antibodies. Immunohistochemical staining results obtained with 7 polyclonal and 21 monoclonal antibodies in sections from paraffin-embedded blocks of these breast cancers were compared. The ability of these antibodies to detect overexpression was extremely variable, providing an important explanation for the variable overexpression rate reported in the literature.

1 Supported in part by Grants CA48780, CA32737, CA36827, and CA50589 from the National Cancer Institute; Grant N01-HD-3-3175 from the National Institute of Child Health and Human Development; Grant IN-21-29/003 and PDT-411 from the American Cancer Society; the Revlon/UCLA Women's Cancer Research Program; and the Molecular Core Laboratory Facilities of the General Clinical Research Centers (National Institutes of Health National Center for Research Resources of the General Clinical Research Centers MO1 RR-43). D. J. S. has a Faculty Research Award from the American Cancer Society.

2 To whom requests for reprints should be addressed, at Department of Pathology—HMR910, U.S.C. School of Medicine, 2011 Zonal Avenue, Los Angeles, CA 90033.

Received 6/ 2/93. Accepted 3/17/94.




This article has been cited by other articles:


Home page
 Clin. Chem.Home page
J. St. J. Thomas
Quality Assurance in Her-2 Testing--Redefining the Gold Standard
Clin. Chem., July 1, 2009; 55(7): 1265 - 1267.
[Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
J Zustin, K Boddin, M C Tsourlakis, E Burandt, M Mirlacher, F Jaenicke, J Izbicki, W Ruether, J M Rueger, C Bokemeyer, et al.
HER-2/neu analysis in breast cancer bone metastases
J. Clin. Pathol., June 1, 2009; 62(6): 542 - 546.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J. S. Ross, E. A. Slodkowska, W. F. Symmans, L. Pusztai, P. M. Ravdin, and G. N. Hortobagyi
The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine
Oncologist, April 1, 2009; 14(4): 320 - 368.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. Sauter, J. Lee, J. M.S. Bartlett, D. J. Slamon, and M. F. Press
Guidelines for Human Epidermal Growth Factor Receptor 2 Testing: Biologic and Methodologic Considerations
J. Clin. Oncol., March 10, 2009; 27(8): 1323 - 1333.
[Abstract] [Full Text] [PDF]

Home page
 Am J Clin PatholHome page
J. M.S. Bartlett, M. Ibrahim, B. Jasani, J. M. Morgan, I. Ellis, E. Kay, Y. Connolly, F. Campbell, A. O'Grady, S. Barnett, et al.
External Quality Assurance of HER2 FISH and ISH Testing: Three Years of the UK National External Quality Assurance Scheme
Am J Clin Pathol, January 1, 2009; 131(1): 106 - 111.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Di Leo, H. L. Gomez, Z. Aziz, Z. Zvirbule, J. Bines, M. C. Arbushites, S. F. Guerrera, M. Koehler, C. Oliva, S. H. Stein, et al.
Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer
J. Clin. Oncol., December 1, 2008; 26(34): 5544 - 5552.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
C. M. Sturgeon, M. J. Duffy, U.-H. Stenman, H. Lilja, N. Brunner, D. W. Chan, R. Babaian, R. C. Bast Jr., B. Dowell, F. J. Esteva, et al.
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers
Clin. Chem., December 1, 2008; 54(12): e11 - e79.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. F. Press, R. S. Finn, D. Cameron, A. Di Leo, C. E. Geyer, I. E. Villalobos, A. Santiago, R. Guzman, A. Gasparyan, Y. Ma, et al.
HER-2 Gene Amplification, HER-2 and Epidermal Growth Factor Receptor mRNA and Protein Expression, and Lapatinib Efficacy in Women with Metastatic Breast Cancer
Clin. Cancer Res., December 1, 2008; 14(23): 7861 - 7870.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
R A Walker
Immunohistochemical markers as predictive tools for breast cancer
J. Clin. Pathol., June 1, 2008; 61(6): 689 - 696.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
L.-Y. Choong, S. Lim, M. C.-S. Loh, X. Man, Y. Chen, W. Toy, M. Pan, C.-S. Chen, A. Poonepalli, M. P. Hande, et al.
Progressive loss of epidermal growth factor receptor in a subpopulation of breast cancers: implications in target-directed therapeutics
Mol. Cancer Ther., November 1, 2007; 6(11): 2828 - 2842.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
S. A. V. Ricardo, F. Milanezi, S. T. Carvalho, D. R. A. Leitao, and F. C. L. Schmitt
HER2 evaluation using the novel rabbit monoclonal antibody SP3 and CISH in tissue microarrays of invasive breast carcinomas
J. Clin. Pathol., September 1, 2007; 60(9): 1001 - 1005.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
J. M S Bartlett, M. Ibrahim, K. Miller, B. Jasani, J. M Morgan, I. Ellis, E. Kay, H. Magee, and S. Barnett
External quality assurance of HER2 fluorescence in situ hybridisation testing: results of a UK NEQAS pilot scheme
J. Clin. Pathol., July 1, 2007; 60(7): 816 - 819.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. N. Harris, F. You, S. J. Schnitt, A. Witkiewicz, X. Lu, D. Sgroi, P. D. Ryan, S. E. Come, H. J. Burstein, B.-A. Lesnikoski, et al.
Predictors of Resistance to Preoperative Trastuzumab and Vinorelbine for HER2-Positive Early Breast Cancer
Clin. Cancer Res., February 15, 2007; 13(4): 1198 - 1207.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. A. Perez, V. J. Suman, N. E. Davidson, S. Martino, P. A. Kaufman, W. L. Lingle, P. J. Flynn, J. N. Ingle, D. Visscher, and R. B. Jenkins
HER2 Testing by Local, Central, and Reference Laboratories in Specimens From the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial
J. Clin. Oncol., July 1, 2006; 24(19): 3032 - 3038.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
N. L. Henry and D. F. Hayes
Uses and abuses of tumor markers in the diagnosis, monitoring, and treatment of primary and metastatic breast cancer.
Oncologist, June 1, 2006; 11(6): 541 - 552.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. Dowsett, J. Houghton, C. Iden, J. Salter, J. Farndon, R. A'Hern, R. Sainsbury, and M. Baum
Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status
Ann. Onc., May 1, 2006; 17(5): 818 - 826.
[Abstract] [Full Text] [PDF]

Home page
 INT J SURG PATHOLHome page
E. Li-Ning-T, R. Ronchetti, C. Torres-Cabala, and M. J. Merino
Role of Chromogenic in Situ Hybridization (CISHTM) in the Evaluation of HER2 Status in Breast Carcinoma: Comparison with Immunohistochemistry and Fish
International Journal of Surgical Pathology, October 1, 2005; 13(4): 343 - 351.
[Abstract] [PDF]

Home page
 J. Clin. Pathol.Home page
R Ainsworth, J M S Bartlett, J J Going, E A Mallon, A Forsyth, J Richmond, W Angerson, A Watters, and B Dunne
IHC for Her2 with CBE356 antibody is a more accurate predictor of Her2 gene amplification by FISH than HercepTestTM in breast carcinoma
J. Clin. Pathol., October 1, 2005; 58(10): 1086 - 1090.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. F. Press, G. Sauter, L. Bernstein, I. E. Villalobos, M. Mirlacher, J.-Y. Zhou, R. Wardeh, Y.-T. Li, R. Guzman, Y. Ma, et al.
Diagnostic Evaluation of HER-2 as a Molecular Target: An Assessment of Accuracy and Reproducibility of Laboratory Testing in Large, Prospective, Randomized Clinical Trials
Clin. Cancer Res., September 15, 2005; 11(18): 6598 - 6607.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Arpino, S. J. Green, D. C. Allred, D. Lew, S. Martino, C. K. Osborne, and R. M. Elledge
HER-2 Amplification, HER-1 Expression, and Tamoxifen Response in Estrogen Receptor-Positive Metastatic Breast Cancer: A Southwest Oncology Group Study
Clin. Cancer Res., September 1, 2004; 10(17): 5670 - 5676.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. M. Slomovitz, R. R. Broaddus, T. W. Burke, N. Sneige, P. T. Soliman, W. Wu, C. C. Sun, M. F. Munsell, D. M. Gershenson, and K. H. Lu
Her-2/neu Overexpression and Amplification in Uterine Papillary Serous Carcinoma
J. Clin. Oncol., August 1, 2004; 22(15): 3126 - 3132.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Isola, M. Tanner, A. Forsyth, T. G. Cooke, A. D. Watters, and J. M. S. Bartlett
Interlaboratory Comparison of HER-2 Oncogene Amplification as Detected by Chromogenic and Fluorescence in situ Hybridization
Clin. Cancer Res., July 15, 2004; 10(14): 4793 - 4798.
[Abstract] [Full Text] [PDF]

Home page
 J. Histochem. Cytochem.Home page
D. Atkins, K.-A. Reiffen, C. L. Tegtmeier, H. Winther, M. S. Bonato, and S. Storkel
Immunohistochemical Detection of EGFR in Paraffin-embedded Tumor Tissues: Variation in Staining Intensity Due to Choice of Fixative and Storage Time of Tissue Sections
J. Histochem. Cytochem., July 1, 2004; 52(7): 893 - 901.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y. Nieto, S. Nawaz, E. J. Shpall, S. I. Bearman, J. Murphy, and R. B. Jones
Long-Term Analysis and Prospective Validation of a Prognostic Model for Patients with High-Risk Primary Breast Cancer Receiving High-Dose Chemotherapy
Clin. Cancer Res., April 15, 2004; 10(8): 2609 - 2617.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. ProteomicsHome page
J. S. Ross, J. A. Fletcher, K. J. Bloom, G. P. Linette, J. Stec, W. F. Symmans, L. Pusztai, and G. N. Hortobagyi
Targeted Therapy in Breast Cancer: The HER-2/neu Gene and Protein
Mol. Cell. Proteomics, April 1, 2004; 3(4): 379 - 398.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. B. Elkin, M. C. Weinstein, E. P. Winer, K. M. Kuntz, S. J. Schnitt, and J. C. Weeks
HER-2 Testing and Trastuzumab Therapy for Metastatic Breast Cancer: A Cost-Effectiveness Analysis
J. Clin. Oncol., March 1, 2004; 22(5): 854 - 863.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
I O Ellis, J Bartlett, M Dowsett, S Humphreys, B Jasani, K Miller, S E Pinder, A Rhodes, and R Walker
Best Practice No 176: Updated recommendations for HER2 testing in the UK
J. Clin. Pathol., March 1, 2004; 57(3): 233 - 237.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
E D Hsi and R R Tubbs
Guidelines for HER2 testing in the UK
J. Clin. Pathol., March 1, 2004; 57(3): 241 - 242.
[Full Text] [PDF]

Home page
 J. Mol. Diagn.Home page
L. M. Gjerdrum, B. S. Sorensen, E. Kjeldsen, F. B. Sorensen, E. Nexo, and S. Hamilton-Dutoit
Real-Time Quantitative PCR of Microdissected Paraffin-Embedded Breast Carcinoma: An Alternative Method for HER-2/neu Analysis
J. Mol. Diagn., February 1, 2004; 6(1): 42 - 51.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
P. Heinmoller, C. Gross, K. Beyser, C. Schmidtgen, G. Maass, M. Pedrocchi, and J. Ruschoff
HER2 Status in Non-Small Cell Lung Cancer: Results from Patient Screening for Enrollment to a Phase II Study of Herceptin
Clin. Cancer Res., November 1, 2003; 9(14): 5238 - 5243.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. T. Junttila, M. Laato, T. Vahlberg, K.-O. Soderstrom, T. Visakorpi, J. Isola, and K. Elenius
Identification of Patients with Transitional Cell Carcinoma of the Bladder Overexpressing ErbB2, ErbB3, or Specific ErbB4 Isoforms: Real-Time Reverse Transcription-PCR Analysis in Estimation of ErbB Receptor Status from Cancer Patients
Clin. Cancer Res., November 1, 2003; 9(14): 5346 - 5357.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
A. Handra-Luca, H. Bilal, J.-C. Bertrand, and P. Fouret
Extra-Cellular Signal-Regulated ERK-1/ERK-2 Pathway Activation in Human Salivary Gland Mucoepidermoid Carcinoma: Association to Aggressive Tumor Behavior and Tumor Cell Proliferation
Am. J. Pathol., September 1, 2003; 163(3): 957 - 967.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J. S. Ross, J. A. Fletcher, G. P. Linette, J. Stec, E. Clark, M. Ayers, W. F. Symmans, L. Pusztai, and K. J. Bloom
The HER-2/neu Gene and Protein in Breast Cancer 2003: Biomarker and Target of Therapy
Oncologist, August 1, 2003; 8(4): 307 - 325.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. A. Bookman, K. M. Darcy, D. Clarke-Pearson, R. A. Boothby, and I. R. Horowitz
Evaluation of Monoclonal Humanized Anti-HER2 Antibody, Trastuzumab, in Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Carcinoma With Overexpression of HER2: A Phase II Trial of the Gynecologic Oncology Group
J. Clin. Oncol., January 15, 2003; 21(2): 283 - 290.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. Birner, G. Oberhuber, M. F. Press, L. Bernstein, K. Flom, and D. Slamon
Is Fluorescence In Situ Hybridization Really Superior to HercepTest?
J. Clin. Oncol., December 1, 2002; 20(23): 4607 - 4609.
[Full Text] [PDF]

Home page
 JCOHome page
M. F. Press, D. J. Slamon, K. J. Flom, J. Park, J.-Y. Zhou, and L. Bernstein
Evaluation of HER-2/neu Gene Amplification and Overexpression: Comparison of Frequently Used Assay Methods in a Molecularly Characterized Cohort of Breast Cancer Specimens
J. Clin. Oncol., July 15, 2002; 20(14): 3095 - 3105.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
D. Gancberg, A. Di Leo, F. Cardoso, G. Rouas, M. Pedrocchi, M. Paesmans, A. Verhest, C. Bernard-Marty, M. J. Piccart, and D. Larsimont
Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites
Ann. Onc., July 1, 2002; 13(7): 1036 - 1043.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Di Leo, D. Gancberg, D. Larsimont, M. Tanner, T. Jarvinen, G. Rouas, S. Dolci, J.-Y. Leroy, M. Paesmans, J. Isola, et al.
HER-2 Amplification and Topoisomerase II{alpha} Gene Aberrations as Predictive Markers in Node-positive Breast Cancer Patients Randomly Treated Either with an Anthracycline-based Therapy or with Cyclophosphamide, Methotrexate, and 5-Fluorouracil
Clin. Cancer Res., May 1, 2002; 8(5): 1107 - 1116.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
R. Tubbs, J. Pettay, M. Skacel, R. Powell, M. Stoler, P. Roche, and J. Hainfeld
Gold-Facilitated in Situ Hybridization : A Bright-Field Autometallographic Alternative to Fluorescence in Situ Hybridization for Detection of HER-2/neu Gene Amplification
Am. J. Pathol., May 1, 2002; 160(5): 1589 - 1595.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. A. Grushko, M. A. Blackwood, P. L. Schumm, F. G. Hagos, M. O. Adeyanju, M. D. Feldman, M. O. Sanders, B. L. Weber, and O. I. Olopade
Molecular-Cytogenetic Analysis of HER-2/neu Gene in BRCA1-associated Breast Cancers
Cancer Res., March 1, 2002; 62(5): 1481 - 1488.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. G. Thomas, T. J. Giordano, D. Sanders, J. S. Biermann, and L. Baker
Absence of HER2/neu Gene Expression in Osteosarcoma and Skeletal Ewing's Sarcoma
Clin. Cancer Res., March 1, 2002; 8(3): 788 - 793.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
Y. Nieto, S. Nawaz, R. B. Jones, E. J. Shpall, P. J. Cagnoni, P. A. McSweeney, A. Baron, C. Razook, S. Matthes, and S. I. Bearman
Prognostic Model for Relapse After High-Dose Chemotherapy With Autologous Stem-Cell Transplantation for Stage IV Oligometastatic Breast Cancer
J. Clin. Oncol., February 1, 2002; 20(3): 707 - 718.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. J. Khan, B. L. King, B. D. Smith, G. L. Smith, M. P. DiGiovanna, D. Carter, and B. G. Haffty
Characterization of the HER-2/neu Oncogene by Immunohistochemical and Fluorescence in Situ Hybridization Analysis in Oral and Oropharyngeal Squamous Cell Carcinoma
Clin. Cancer Res., February 1, 2002; 8(2): 540 - 548.
[Abstract] [Full Text] [PDF]

Home page
 Annals of Clinical & Laboratory ScienceHome page
D. W. Nichols, D. J. Wolff, S. Self, J. S. Metcalf, D. Jacobs, R. Kneuper-Hall, and J. C. Cate IV
A Testing Algorithm for Determination of HER2 Status in Patients with Breast Cancer
Ann. Clin. Lab. Sci., January 1, 2002; 32(1): 3 - 11.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Dowsett, C. Harper-Wynne, I. Boeddinghaus, J. Salter, M. Hills, M. Dixon, S. Ebbs, G. Gui, N. Sacks, and I. Smith
HER-2 Amplification Impedes the Antiproliferative Effects of Hormone Therapy in Estrogen Receptor-positive Primary Breast Cancer
Cancer Res., December 1, 2001; 61(23): 8452 - 8458.
[Abstract] [Full Text] [PDF]

Home page
 J Natl Cancer Inst MonogrHome page
G. W. Sledge Jr.
Is HER-2/neu a Predictor of Anthracycline Utility? No.
J Natl Cancer Inst Monographs, December 1, 2001; 2001(30): 85 - 87.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. A. Coronella, P. Telleman, G. A. Kingsbury, T. D. Truong, S. Hays, and R. P. Junghans
Evidence for an Antigen-driven Humoral Immune Response in Medullary Ductal Breast Cancer
Cancer Res., November 1, 2001; 61(21): 7889 - 7899.
[Abstract] [Full Text] [PDF]

Home page
 Annals of Clinical & Laboratory ScienceHome page
W. K. Funkhouser and K. Kaiser-Rogers
Significance of, and Optimal Screening for, HER-2 Gene Amplification and Protein Overexpression in Breast Carcinoma
Ann. Clin. Lab. Sci., October 1, 2001; 31(4): 349 - 358.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
W. N. Hait
The Prognostic and Predictive Values of ECD-HER-2
Clin. Cancer Res., September 1, 2001; 7(9): 2601 - 2604.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Konecny, M. Untch, J. Arboleda, C. Wilson, S. Kahlert, B. Boettcher, M. Felber, M. Beryt, S. Lude, H. Hepp, et al.
HER-2/neu and Urokinase-Type Plasminogen Activator and Its Inhibitor in Breast Cancer
Clin. Cancer Res., August 1, 2001; 7(8): 2448 - 2457.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. Birner, G. Oberhuber, J. Stani, C. Reithofer, H. Samonigg, H. Hausmaninger, E. Kubista, W. Kwasny, D. Kandioler-Eckersberger, M. Gnant, et al.
Evaluation of the United States Food and Drug Administration-approved Scoring and Test System of HER-2 Protein Expression in Breast Cancer
Clin. Cancer Res., June 1, 2001; 7(6): 1669 - 1675.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R.R. Tubbs, J.D. Pettay, P.C. Roche, M.H. Stoler, R.B. Jenkins, and T.M. Grogan
Discrepancies in Clinical Laboratory Testing of Eligibility for Trastuzumab Therapy: Apparent Immunohistochemical False-Positives Do Not Get the Message
J. Clin. Oncol., May 15, 2001; 19(10): 2714 - 2721.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Braun, G. Schlimok, I. Heumos, G. Schaller, L. Riethdorf, G. Riethmüller, and K. Pantel
erbB2 Overexpression on Occult Metastatic Cells in Bone Marrow Predicts Poor Clinical Outcome of Stage I-III Breast Cancer Patients
Cancer Res., March 1, 2001; 61(5): 1890 - 1895.
[Abstract] [Full Text]

Home page
 JCOHome page
S. Eppenberger-Castori, W. Kueng, C. Benz, R. Caduff, Z. Varga, F. Bannwart, D. Fink, H. Dieterich, M. Hohl, H. Muller, et al.
Prognostic and Predictive Significance of ErbB-2 Breast Tumor Levels Measured by Enzyme Immunoassay
J. Clin. Oncol., February 1, 2001; 19(3): 645 - 656.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Lebeau, D. Deimling, C. Kaltz, A. Sendelhofert, A. Iff, B. Luthardt, M. Untch, and U. Lohrs
HER-2/neu Analysis in Archival Tissue Samples of Human Breast Cancer: Comparison of Immunohistochemistry and Fluorescence In Situ Hybridization
J. Clin. Oncol., January 15, 2001; 19(2): 354 - 363.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
I O Ellis, M Dowsett, J Bartlett, R Walker, T Cooke, W Gullick, B Gusterson, E Mallon, and P Barrett Lee
Recommendations for HER2 testing in the UK
J. Clin. Pathol., December 1, 2000; 53(12): 890 - 892.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Ferrero-Poüs, K. Hacène, C. Bouchet, V. Le Doussal, M. Tubiana-Hulin, and F. Spyratos
Relationship between c-erbB-2 and Other Tumor Characteristics in Breast Cancer Prognosis
Clin. Cancer Res., December 1, 2000; 6(12): 4745 - 4754.
[Abstract] [Full Text]

Home page
 JCOHome page
G. Pauletti, S. Dandekar, H. Rong, L. Ramos, H. Peng, R. Seshadri, and D. J. Slamon
Assessment of Methods for Tissue-Based Detection of the HER-2/neu Alteration in Human Breast Cancer: A Direct Comparison of Fluorescence In Situ Hybridization and Immunohistochemistry
J. Clin. Oncol., November 1, 2000; 18(21): 3651 - 3664.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
M. Tanner, D. Gancberg, A. Di Leo, D. Larsimont, G. Rouas, M. J. Piccart, and J. Isola
Chromogenic in Situ Hybridization : A Practical Alternative for Fluorescence in Situ Hybridization to Detect HER-2/neu Oncogene Amplification in Archival Breast Cancer Samples
Am. J. Pathol., November 1, 2000; 157(5): 1467 - 1472.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Colomer, S. Montero, A. Lluch, B. Ojeda, A. Barnadas, A. Casado, B. Massutí, H. Cortés-Funes, and B. Lloveras
Circulating HER2 Extracellular Domain and Resistance to Chemotherapy in Advanced Breast Cancer
Clin. Cancer Res., June 1, 2000; 6(6): 2356 - 2362.
[Abstract] [Full Text]

Home page
 JCOHome page
Y. Nieto, P. J. Cagnoni, S. Nawaz, E. J. Shpall, R. Yerushalmi, B. Cook, P. Russell, J. McDermit, J. Murphy, S. I. Bearman, et al.
Evaluation of the Predictive Value of Her-2/neu Overexpression and p53 Mutations in High-Risk Primary Breast Cancer Patients Treated With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation
J. Clin. Oncol., May 10, 2000; 18(10): 2070 - 2080.
[Abstract] [Full Text] [PDF]

Home page
 J. Mol. Diagn.Home page
R. R. Tubbs, J. Pettay, P. Roche, M. H. Stoler, R. Jenkins, J. Myles, and T. Grogan
Concomitant Oncoprotein Detection with Fluorescence in Situ Hybridization (CODFISH): A Fluorescence-Based Assay Enabling Simultaneous Visualization of Gene Amplification and Encoded Protein Expression
J. Mol. Diagn., May 1, 2000; 2(2): 78 - 83.
[Abstract] [Full Text]

Home page
 J. Clin. Pathol.Home page
A Rhodes, B Jasani, A J Balaton, and K D Miller
Immunohistochemical demonstration of oestrogen and progesterone receptors: correlation of standards achieved on in house tumours with that achieved on external quality assessment material in over 150 laboratories from 26 countries
J. Clin. Pathol., April 1, 2000; 53(4): 292 - 301.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Stark, B. S. Hulka, S. Joens, D. Novotny, A. D. Thor, L. E. Wold, M. J. Schell, L. J. Melton III, E. T. Liu, and K. Conway
HER-2/neu Amplification in Benign Breast Disease and the Risk of Subsequent Breast Cancer
J. Clin. Oncol., January 14, 2000; 18(2): 267 - 267.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Isola, L. Chu, S. DeVries, K. Matsumura, K. Chew, B. M. Ljung, and F. M. Waldman
Genetic Alterations in ERBB2-amplified Breast Carcinomas
Clin. Cancer Res., December 1, 1999; 5(12): 4140 - 4145.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
W. Xia, Y.-K. Lau, H.-Z. Zhang, F.-Y. Xiao, D. A. Johnston, A.-R. Liu, L. Li, R. L. Katz, and M.-C. Hung
Combination of EGFR, HER-2/neu, and HER-3 Is a Stronger Predictor for the Outcome of Oral Squamous Cell Carcinoma Than Any Individual Family Members
Clin. Cancer Res., December 1, 1999; 5(12): 4164 - 4174.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
I. Bieche, P. Onody, I. Laurendeau, M. Olivi, D. Vidaud, R. Lidereau, and M. Vidaud
Real-Time Reverse Transcription-PCR Assay for Future Management of ERBB2-based Clinical Applications
Clin. Chem., August 1, 1999; 45(8): 1148 - 1156.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. W. Jacobs, A. M. Gown, H. Yaziji, M. J. Barnes, and S. J. Schnitt
Comparison of Fluorescence In Situ Hybridization and Immunohistochemistry for the Evaluation of HER-2/neu in Breast Cancer
J. Clin. Oncol., July 1, 1999; 17(7): 1974 - 1974.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. W. Jacobs, A. M. Gown, H. Yaziji, M. J. Barnes, and S. J. Schnitt
Specificity of HercepTest in Determining HER-2/neu Status of Breast Cancers Using the United States Food and Drug Administration-Approved Scoring System
J. Clin. Oncol., July 1, 1999; 17(7): 1983 - 1983.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
E. Ruijter, C. van de Kaa, G. Miller, D. Ruiter, F. Debruyne, and J. Schalken
Molecular Genetics and Epidemiology of Prostate Carcinoma
Endocr. Rev., February 1, 1999; 20(1): 22 - 45.
[Abstract] [Full Text]

Home page
 J. Cell Sci.Home page
P Nagy, A Jenei, A. Kirsch, J Szollosi, S Damjanovich, and T. Jovin
Activation-dependent clustering of the erbB2 receptor tyrosine kinase detected by scanning near-field optical microscopy
J. Cell Sci., January 6, 1999; 112(11): 1733 - 1741.
[Abstract] [PDF]

Home page
 The OncologistHome page
J. S. Ross and J. A. Fletcher
The HER-2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy
Oncologist, August 1, 1998; 3(4): 237 - 252.
[Abstract] [Full Text]

Home page
 Clin. Chem.Home page
F. Revillion, L. Hornez, and J.-P. Peyrat
Quantification of c-erbB-2 gene expression in breast cancer by competitive RT-PCR
Clin. Chem., November 1, 1997; 43(11): 2114 - 2120.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1994 by the American Association for Cancer Research.